Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

• DOI: 10.15585/mmwr.mm7034e2
• Publication Date: 2021-08-18T14:54:57Z
• Authors: Mark W. Tenforde; Wesley H. Self; Eric A. Naioti; Adit A. Ginde; David J. Douin; Samantha M. Olson; H. Keipp Talbot; Jonathan D. Casey; Nicholas M. Mohr; Anne Zepeski; Manjusha Gaglani; Tresa McNeal; Shekhar Ghamande; Nathan I. Shapiro; Kevin W. Gibbs; D. Clark Files; David N. Hager; Arber Shehu; Matthew E. Prekker; Heidi L. Erickson; Michelle N. Gong; Amira Mohamed; Daniel J. Henning; Jay S. Steingrub; Ithan D. Peltan; Samuel M. Brown; Emily T. Martin; Arnold S. Monto; Akram Khan; Catherine L. Hough; Laurence W. Busse; Caitlin C. ten Lo...; Abhijit Duggal; Jennifer G. Wilson; Alexandra June Go...; Nida Qadir; Steven Y. Chang; Christopher Mallow; Carolina Rivas; Hilary M. Babcock; Jennie H. Kwon; Matthew C. Exline; Natasha Halasa; James D. Chappell; Adam S. Lauring; Carlos G. Grijalva; Todd W. Rice; Ian D. Jones; William B. Stubbl...; Adrienne Baughman; Kelsey N. Womack; Christopher J. Li...; Kimberly W. Hart; Yuwei Zhu; Meagan Stephenson; Stephanie J. Schrag; Miwako Kobayashi; Jennifer R. Verani; Manish M. Patel; ; ; Nicole Calhoun; Kempapura Murthy; Judy Herrick; Amanda McKillop; Eric Hoffman; Martha Zayed; Michael Smith; Natalie Settele; Jason Ettlinger; Elisa Priest; Jennifer Thomas; Alejandro Arroliga; Madhava Beeram; Ryan Kindle; Lori-Ann Kozikowski; Lesley De Souza; Scott Ouellette; Sherell Thornton-...; Patrick Tyler; Omar Mehkri; Kiran Ashok; Susan Gole; Alexander King; Bryan Poynter; Nicholas Stanley; Audrey Hendrickson; Ellen Maruggi; Tyler Scharber; Jeffrey Jorgensen; Robert Bowers; Jennifer King; Valerie Aston; Brent Armbruster; Richard E. Rothman; Rahul Nair; Jen-Ting (Tina) Chen; Sarah Karow; Emily Robart; Paulo Nunes Maldo...; Maryiam Khan; Preston So; Joe Levitt; Cynthia Perez; Anita Visweswaran; Jonasel Roque; Adreanne Rivera; Trevor Frankel; Michelle Howell; Jennifer Friedel; Jennifer Goff; David Huynh; Michael Tozier; Conner Driver; Michael Carricato; Alexandra Foster; Paul Nassar; Lori Stout; Zita Sibenaller; Alicia Walter; Jasmine Mares; Logan Olson; Bradley Clinansmith; Carolina Rivas; Hayley Gershengorn; EJ McSpadden; Rachel Truscon; Anne Kaniclides; Lara Thomas; Ramsay Bielak; Weronika Damek Va...; Rebecca Fong; William J. Fitzsi...; Christopher Blair; Andrew L. Valesano; Julie Gilbert; Christine D. Crider; Kyle A. Steinbock; Thomas C. Paulson; Layla A. Anderson; Christy Kampe; Jakea Johnson; Rendie McHenry; Marcia Blair; Douglas Conway; Mary LaRose; Leigha Landreth; Madeline Hicks; Lisa Parks; Jahnavi Bongu; David McDonald; Candice Cass; Sondra Seiler; David Park; Tiffany Hink; Meghan Wallace; Carey-Ann Burnham; Olivia G. Arter
• Keywords: Receipt

Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability protection. In an evaluation at 21 hospitals in 18 states, the duration mRNA vaccine (Pfizer-BioNTech or Moderna) (VE) was assessed among adults aged ≥18 years. Among 3,089 hospitalized (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), median age 59 years, 48.7% were female, 21.1% had immunocompromising condition. Overall, 141 (11.8%) 988 (52.1%) controls fully vaccinated (defined as receipt second dose Pfizer-BioNTech Moderna ≥14 days before illness onset), with a interval 65 (range = 14-166 days) dose. VE hospitalization during full surveillance period 86% (95% confidence [CI] 82%-88%) overall 90% CI 87%-92%) without conditions. COVID-19- associated 82%-90%) 2-12 weeks 84% 77%-90%) 13-24 from dose, no significant change between these periods (p 0.854). Whole genome sequencing 454 case-patient specimens found that 242 (53.3%) belonged B.1.1.7 (Alpha) lineage 74 (16.3%) B.1.617.2 (Delta) lineage. Effectiveness sustained over 24-week period, including groups higher risk for severe COVID-19; ongoing monitoring new SARS-CoV-2 variants emerge. To reduce their hospitalization, all eligible persons should be offered vaccination.